Watch this video summary showcasing the key results from the SOLSTICE trial—a multicenter, randomized, open-label, active-controlled study. The trial evaluated eight weeks of treatment with maribavir compared to investigator-assigned therapy (IAT), which included conventional antivirals, in recipients of hematopoietic stem cell transplants or solid organ transplants. Participants had CMV infections that were refractory, with or without resistance, to conventional antiviral therapies such as ganciclovir, valganciclovir, foscarnet, or cidofovir.
C-APROM/BE/LIV/0027
SOLSTICE Factsheet
Looking for a quick overview of the key takeaways from the SOLSTICE trial? Download the factsheet below for all the essential insights!
SOLSTICE Trial Publication
Would you like to read the full study, as published in Clinical Infectious Diseases (Volume 75, Issue 4)?
Download it below!
